• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis AG Common Stock (NY:NVS)

    123.79 +1.18 (+0.96%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Novartis AG Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    38 39 Next >
    Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW
    Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW 
    Via The Motley Fool
    Topics ETFs
    AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
    The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
    Via TokenRing AI
    Topics Animal Testing Artificial Intelligence Economy
    The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
    The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy
    Earnings Scheduled For October 28, 2025
     
    Via Benzinga
    Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis
    Via Stocktwits
    AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
    San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
    Via TokenRing AI
    Topics Artificial Intelligence Supply Chain
    AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
    Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
    Via TokenRing AI
    Topics Artificial Intelligence Intellectual Property
    What to Expect from Novartis's Earnings
     
    Via Benzinga
    AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
    The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
    Via TokenRing AI
    Topics Animal Testing Artificial Intelligence Economy
    Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
    Novartis is set to boost its developmental pipeline with this acquisition. 
    Via The Motley Fool
    Here's My Favorite Passive Income Investment
    International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees. 
    Via The Motley Fool
    Topics ETFs
    Is the Market Bullish or Bearish on Novartis AG?
     
    Via Benzinga
    United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short
    Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
    Via Investor's Business Daily
    Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter
    Generic competition had a 7 percentage-point negative impact on the company's biggest drug. 
    Via Investor's Business Daily
    Novartis Maintains Outlook Even As Generics Bite Into Profits
    Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results. 
    Via Benzinga
    'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours
    U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier... 
    Via Benzinga
    Is It Too Late To Buy Avidity Stock After Novartis Deal?
    Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday. 
    Via Talk Markets
    Why Dyne Therapeutics Stock Crushed the Market on Monday
    Biotechs like it are clearly valuable to strategic acquirers. 
    Via The Motley Fool
    Wall Street Soars as Qualcomm Ignites the AI Race
    Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips. 
    Via Chartmill
    Topics Artificial Intelligence Stocks
    Why Avidity Biosciences Stock Blasted 42% Higher Today
    If all goes well, the company will be part of a much larger enterprise starting next year. 
    Via The Motley Fool
    Avidity Biosciences Soars After $72 Per Share Novartis Takeover
    Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral. 
    Via Benzinga
    Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today
    Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
    Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
    Via Benzinga
    Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today
    Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
    Via Stocktwits
    Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus
    U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher. 
    Via Benzinga
    Topics Stocks
    Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
    San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
    Via MarketMinute
    Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock
    Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program. 
    Via Benzinga
    AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
    The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
    Via TokenRing AI
    Topics Animal Testing Artificial Intelligence
    Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain
    Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    38 39 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.